These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 17995975)

  • 1. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn.
    Yoeruek E; Ziemssen F; Henke-Fahle S; Tatar O; Tura A; Grisanti S; Bartz-Schmidt KU; Szurman P;
    Acta Ophthalmol; 2008 May; 86(3):322-8. PubMed ID: 17995975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety profile of topical VEGF neutralization at the cornea.
    Bock F; Onderka J; Rummelt C; Dietrich T; Bachmann B; Kruse FE; Schlötzer-Schrehardt U; Cursiefen C
    Invest Ophthalmol Vis Sci; 2009 May; 50(5):2095-102. PubMed ID: 19151400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasminogen kringle 5 inhibits alkali-burn-induced corneal neovascularization.
    Zhang Z; Ma JX; Gao G; Li C; Luo L; Zhang M; Yang W; Jiang A; Kuang W; Xu L; Chen J; Liu Z
    Invest Ophthalmol Vis Sci; 2005 Nov; 46(11):4062-71. PubMed ID: 16249481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model.
    Papathanassiou M; Theodossiadis PG; Liarakos VS; Rouvas A; Giamarellos-Bourboulis EJ; Vergados IA
    Am J Ophthalmol; 2008 Mar; 145(3):424-431. PubMed ID: 18207123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis.
    Hosseini H; Nejabat M; Mehryar M; Yazdchi T; Sedaghat A; Noori F
    Clin Exp Ophthalmol; 2007 Nov; 35(8):745-8. PubMed ID: 17997779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum eyedrops antagonize the anti(lymph)angiogenic effects of bevacizumab in vitro and in vivo.
    Hos D; Koch KR; Bucher F; Bock F; Cursiefen C; Heindl LM
    Invest Ophthalmol Vis Sci; 2013 Sep; 54(9):6133-42. PubMed ID: 23970469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the effects of resveratrol and bevacizumab on experimental corneal alkali burn.
    Doganay S; Firat PG; Cankaya C; Kirimlioglu H
    Burns; 2013 Mar; 39(2):326-30. PubMed ID: 22922008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The different effects of early and late bevacizumab (Avastin) injection on inhibiting corneal neovascularization and conjunctivalization in rabbit limbal insufficiency.
    Lin CT; Hu FR; Kuo KT; Chen YM; Chu HS; Lin YH; Chen WL
    Invest Ophthalmol Vis Sci; 2010 Dec; 51(12):6277-85. PubMed ID: 20435600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis.
    Chen WL; Lin CT; Lin NT; Tu IH; Li JW; Chow LP; Liu KR; Hu FR
    Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1659-65. PubMed ID: 18997093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doxycycline enhances the inhibitory effects of bevacizumab on corneal neovascularization and prevents its side effects.
    Su W; Li Z; Li Y; Lin M; Yao L; Liu Y; He Z; Wu C; Liang D
    Invest Ophthalmol Vis Sci; 2011 Nov; 52(12):9108-15. PubMed ID: 22039247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats.
    Hashemian MN; Moghimi S; Kiumehr S; Riazi M; Amoli FA
    Ophthalmic Res; 2009; 42(2):90-5. PubMed ID: 19546599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization.
    Habot-Wilner Z; Barequet IS; Ivanir Y; Moisseiev J; Rosner M
    Acta Ophthalmol; 2010 Dec; 88(8):862-7. PubMed ID: 19549103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis.
    Bock F; Onderka J; Dietrich T; Bachmann B; Kruse FE; Paschke M; Zahn G; Cursiefen C
    Invest Ophthalmol Vis Sci; 2007 Jun; 48(6):2545-52. PubMed ID: 17525183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).
    Kim TI; Kim SW; Kim S; Kim T; Kim EK
    Cornea; 2008 Apr; 27(3):349-52. PubMed ID: 18362666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-VEGF therapy (bevacizumab) for sulfur mustard-induced corneal neovascularization associated with delayed limbal stem cell deficiency in rabbits.
    Kadar T; Amir A; Cohen L; Cohen M; Sahar R; Gutman H; Horwitz V; Dachir S
    Curr Eye Res; 2014 May; 39(5):439-50. PubMed ID: 24215293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats.
    Hashemian MN; Z-Mehrjardi H; Moghimi S; Tahvildari M; Mojazi-Amiri H
    Ophthalmic Res; 2011; 46(1):50-4. PubMed ID: 21212709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical bevacizumab and ocular surface neovascularization in patients with stevens-johnson syndrome.
    Uy HS; Chan PS; Ang RE
    Cornea; 2008 Jan; 27(1):70-3. PubMed ID: 18245970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization.
    Koenig Y; Bock F; Horn F; Kruse F; Straub K; Cursiefen C
    Graefes Arch Clin Exp Ophthalmol; 2009 Oct; 247(10):1375-82. PubMed ID: 19415316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of corneal neovascularization by topical bevacizumab (Anti-VEGF) and Sunitinib (Anti-VEGF and Anti-PDGF) in an animal model.
    Pérez-Santonja JJ; Campos-Mollo E; Lledó-Riquelme M; Javaloy J; Alió JL
    Am J Ophthalmol; 2010 Oct; 150(4):519-528.e1. PubMed ID: 20591397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Vascular morphological and microdensity changes of corneal neovascularization induced by topical bevacizumab and sunitinib in an animal model].
    Pérez-Santonja JJ; Campos-Mollo E; Lledó-Riquelme M; Fernández-Sánchez L; Cuenca-Navarro N
    Arch Soc Esp Oftalmol; 2013 Dec; 88(12):473-81. PubMed ID: 24257257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.